<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126141">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02009774</url>
  </required_header>
  <id_info>
    <org_study_id>ADOPTION</org_study_id>
    <nct_id>NCT02009774</nct_id>
  </id_info>
  <brief_title>Accuracy of the Optical Diagnosis of Small Colonic Polyps Using the Nice Classification</brief_title>
  <acronym>ADOPTION</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Olympus Europe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adenomas and hyperplastic polyps are polypoid lesion and may occur at any location in the
      colon. At the present moment, all polyps should be resected endoscopically, although only
      adenomas, but not hyperplastic polyps have the potential to develop colorectal cancer. This
      approach enables the conduction of microscopic investigations of the lesions. By today, only
      the pathological diagnosis can distinguish exactly between adenomas and hyperplastic polyps.
      Some studies have investigated the value of the socalled optical biopsy method. Optical
      biopsy means the visual assessment of the polyp and the determination of a diagnosis solely
      on behalf of optical criteria. This method is conducted in real time during colonoscopy. If
      it can be shown, that endoscopist using optical biopsy are able to predict histopathological
      diagnoses of colonic polyps sufficiently this would possibly lead to simplification of
      diagnostic procedures. For instance, it would be conceivable to resect hyperplastic polyps
      and small adenomas and discard them without further assessment by a pathologist.
      Gastroenterological societies demand for a 90 percent accordance between diagnoses set by
      endoscopists and pathologists as a prerequisite for the implementation of the optical biopsy
      method.

      In this study we want to proof that the use of a new narrow-band imaging (NBI) tool (Exera
      III, Olmpus) is capable to rise accuracy of optically ascertained  diagnoses of colonic
      polyps. NBI is a light filter tool which can be activated by pressing a button at the
      endoscope. NBI function leads to an endoscopic picture which appears blue and enables
      endoscopists to better assess surface structures and vascular patterns.

      In a prospective randomised multicenter setting we plan to conduct colonoscopy in 380
      patients. Half of the patients will be examined  without use of NBI (control arm). In these
      cases colonoscopists will assess optical diagnosis of polyps without turning on the NBI
      tool. If polyps are detected in patients belonging to the intervention arm NBI will be used
      and optical diagnosis will be determined using the NICE (NBI International Colorectal
      Endoscopic) classification. All polyps will be resected and send to pathology for further
      microscopic assessment. After completing the trial we aim to compare accuracy  of the
      optical diagnosis in both groups. Our hypothesis is, that by using  the new NBI tool
      accuracy (accordance between optical and histopathological diagnosis) can be increased from
      78% to 90%.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Accuracy optical biopsy</measure>
    <time_frame>up to 2 weeks (participants will be followed for the duration of hospital stay or outpatient treatment, an expected average of 2 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>After obtaining the histopathological diagnosis of resected polyps (approximately 3 days - 2 weeks after colonoscopy ) accuracy of optical diagnosis can be determined</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adenoma detection rate</measure>
    <time_frame>up to 2 weeks (participants will be followed for the duration of hospital stay or outpatient treatment, an expected average of 2 weeks)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Colon Adenoma</condition>
  <condition>Colorectal Carcinoma</condition>
  <condition>Hyperplastic Polyp</condition>
  <arm_group>
    <arm_group_label>Controll group</arm_group_label>
    <description>Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined WITHOUT using the NBI function of the scope.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <description>Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined WITH THE HELP OF the NBI function of the scope.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>NBI Function</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>NBI Function integrated in the CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Colon polyps
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited at the three participating study centers (Munich, Frankfurt,
        Berlin). Two of the three centers are  tertiary referral-centres whereas the last one is a
        major regional hospital. All patients undergo colonoscopy for medical indications.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  medical indication for colonoscopy

          -  age &gt;18 years

          -  written consent given by patient

        Exclusion Criteria:

          -  age &lt; 18 years

          -  patients denying written consent

          -  pregnant women

          -  ASA class IV, V and VI

          -  known contraindication for polyp resection

          -  indication for colonoscopy: preknown adenoma/polyp/carcinoma

          -  indication for colonoscopy: emergency (e.g. severe rectal bleeding)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Klare, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum rechts der Isar der Technischen Universität München</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan von Delius, MD</last_name>
    <role>Study Director</role>
    <affiliation>Klinikum rechts der Isar der Technischen Universität München</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jörg Albert, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medizinische Klinik I University Hospital Frankfurt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ellen C Nötzel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Innere Medizin I, Sana Klinikum Lichtenberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Klare, MD</last_name>
    <phone>+49 89 4140 5055</phone>
    <email>peter.klare@lrz.tum.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefan von Delius, MD</last_name>
    <phone>+49 89 4140 5975</phone>
    <email>stefan_ruckert@yahoo.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>II Medizinische Klinik am Klinikum rechts der Isar der Technischen Universität München</name>
      <address>
        <city>Munich</city>
        <state>Bayern</state>
        <zip>81677</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Klare, MD</last_name>
      <phone>+49 89 4140 5055</phone>
      <email>peter.klare@lrz.tum.de</email>
    </contact>
    <contact_backup>
      <last_name>Stefan von Delius, MD</last_name>
      <phone>+49 89 4140 5973</phone>
      <email>stefan_ruckert@yahoo.de</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Klare, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik I des Universitätsklinikums Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Albert, MD</last_name>
      <phone>+49 69 6301 5297</phone>
      <email>Joerg.Albert@kgu.de</email>
    </contact>
    <investigator>
      <last_name>Jörg Albert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innere Medizin I am Sana Klinikum Lichtenberg</name>
      <address>
        <city>Berlin</city>
        <zip>10365</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen C Nötzel, MD</last_name>
      <phone>+49 30 5518 2211</phone>
      <email>E.Noetzel@sana-kl.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>April 16, 2014</lastchanged_date>
  <firstreceived_date>December 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universität München</investigator_affiliation>
    <investigator_full_name>Dr. Peter Klare</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Colonoscopy</keyword>
  <keyword>Adenoma detection rate</keyword>
  <keyword>Narrow band imaging</keyword>
  <keyword>Optical biopsy</keyword>
  <keyword>Accuracy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Polyps</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
